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A B S T R A C T
Background: The increasing prevalence and adverse outcomes associated with opioid analgesia use in
women of reproductive age have become a significant public health issue internationally, with use during
pregnancy potentially affecting maternal and infant health outcomes.
Objective: This study aims to provide national estimates of chronic pain, pain severity and analgesia use in
Australian women of reproductive age by pregnancy status.
Method: Data were obtained from the Australian Bureau of Statistics 2011–12 National Health Survey
(n = 20,426). Weighting was applied to sample data to obtain population estimates. For this study data
were analysed for pregnant (n = 166, N = 192,617) and non-pregnant women (n = 4710, N = 5,256,154) of
reproductive age (15–49 years).
Results: Chronic or reoccurring pain was reported in 5.1% of pregnant women and 9.7% of non-pregnant
women, and 0.7% and 2.6% of pregnant and non-pregnant women reported recent opioid analgesia use
respectively. Moderate-to-very severe pain was more common in pregnant than non-pregnant women
taking opioid analgesics, and no pain and very mild-to-mild pain in non-pregnant women.
Conclusion: Approximately 1 in 20 pregnant Australian women have chronic or reoccurring pain. Opioid
analgesia was used by around 1% of Australian pregnant women during a two-week period, with use
associated with moderate-to-very severe pain. Given that the safety of many analgesic medications in
pregnancy remains unknown, pregnant women and health professionals require accurate, up-to-date
information on the risks and benefits of analgesic use during pregnancy. Further evidence on the
decision-making processes of pregnant women with pain should assist health professionals maximise
outcomes for mothers and infants.
© 2018 Published by Elsevier Ltd on behalf of Australian College of Midwives.
Statement of significance
Problem or issue
There have been significant increases in the use of opioid
analgesia internationally, including in women of reproduc-
tive age. The prevalence of pain and opioid analgesia use in
Australian pregnant women remains unknown.
What is already known
Chronic pain in women of reproductive age is not uncom-
mon and is often associated with the use of analgesic
medications, including opioid analgesia. In the US and
Canada, the increasing use of opioid analgesic medications
in pregnant and reproductive aged women has become a
major public health issue, leading to significant impacts
upon maternal and infant health outcomes.
What this paper adds
We establish that in Australia, 1 in 20 pregnant women have
experienced chronic or reoccurring pain over the most
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women reported recent use of opioid analgesic medicationses.
everity and analgesia use in Australian women of reproductive age,
2 A.M. Miller et al. / Women and Birth xxx (2018) xxx–xxx
G Model
WOMBI 822 No. of Pages 7and this use was associated with moderate-to-very severe
pain.
1. Introduction
Sex differences in both pain frequency and intensity have been
well described in the international literature. Women are
disproportionately or even solely affected by many conditions
which cause or contribute to chronic pain.1 Many of these
conditions are more likely to occur during the reproductive years
than at any other time of life.1 Thus, while it is well known that the
prevalence of chronic pain increases with older age, chronic pain in
women of reproductive age is not uncommon.2,3
During pregnancy pain may occur as a result of an existing
health condition, due to an underlying medical illness, or as a
consequence of physiological changes associated with
pregnancy.4–8 In some cases women may have chronic pain of
multiple aetiologies, including pre-pregnancy pain conditions,
which have become exacerbated by the developing pregnancy.9,10
Though not exhaustive, examples of health conditions and
illnesses which may cause chronic or reoccurring pain in women
during the reproductive years include: systemic lupus erythema-
tosus, rheumatoid arthritis,11 the Ehlers–Danlos syndromes,12
temporomandibular disorder,13 reoccurring migraine,14 chronic
back pain,15,16 fibromyalgia,17,18 Crohn’s disease, ulcerative colitis,19
endometriosis and other causes of chronic pelvic pain, both
gynaecologic and non-gynaecologic.20,21 For the majority of these
conditions prevalence rates specific to pregnant women are not
known.
Pregnancy related pain and discomfort are common and may
include conditions such as lower back pain and pelvic joint
pain.22,23 Pregnancy can be an especially difficult period for
women with severe pain.24 In a sample of South Australian women
interviewed retrospectively, 61% of women described the lower
back pain they experienced in pregnancy as moderately severe,
with a further 9% reporting their pain as so severe it was
completely debilitating.24 Women with pregnancy-related sym-
physis pubis dysfunction also often report experiencing extreme,
ongoing pain, which can have a substantial impact upon quality of
life.25
Many women with painful health conditions may have an
ongoing requirement for analgesic medications, including during
pregnancy.5,26 However, the safety of many analgesic medications
during pregnancy has not been definitively established.4,8
The use of opioid analgesic medications for chronic pain
management in the general population has been the source of
much research. Their use remains an issue of debate due primarily
to concerns pertaining to safety and the effectiveness of treatment,
particularly in populations at high risk of adverse events.27 One
concern is the increasing use of opioid analgesic medications
among women of childbearing age. This phenomenon has been
documented in both the United States28,29 and Canada,30 where
prescription opioid use and abuse has been described as being at
epidemic proportions. A recent study by Patrick et al. highlighted
that almost one third of pregnant women had filled a prescription
for at least one opioid analgesic medication during pregnancy,
contributing to neonatal complications including low birth weight
and neonatal abstinence syndrome (NAS).29 Other reports of the
prevalence of opioid use during pregnancy range from 6% in
Norway31 to an estimated 41% in some areas of the United States.32
The outcomes of foetal exposure to maternal medication use are
dependent upon the stage of embryonic or foetal development, in
addition to maternal and placental clearance of the medica-
tion.33,34 The early stages of the first trimester of pregnancy are aPlease cite this article in press as: A.M. Miller, et al., Chronic pain, pain s
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are associated with medication exposures occur during this period,
potentially before many women realise they are pregnant.4 Though
opioid medications were thought to have no association with an
increased risk of congenital malformations, more recent observa-
tional studies have found associations between opioid analgesia
use during pregnancy and several birth defects, including multiple
congenital heart defects, neural tube defects and abdominal wall
defects such as gastroschisis.5–8,35
This study aims to provide the first nationally representative
data on the prevalence of chronic pain, pain severity and analgesia
use in Australian women of reproductive age by pregnancy status.
2. Methods
Data were obtained from the 2011–12 Australian National
Health Survey (NHS) in which data were collected using a stratified
multistage area sample (n = 20,426) across Australia.36 Interviews
were conducted face-to-face in the participants’ homes between
March 2011 and March 2012.37 Sample results were weighted to
infer an Australian population estimate at the time of the survey
(N = 22,105,281). For this study, data were analysed for the
weighted population of pregnant (N=192,617) and non-pregnant
women (N = 5,256,154) in Australia aged 15–49 years. Data items
analysed comprised chronic or recurring pain in the previous six
months, bodily pain (severity), opioid analgesia and non-opioid
analgesia use.
Pregnancy status was self-reported. Females aged 10 years and
over were asked if any of the following applied: have never
menstruated, currently pregnant, currently breast feeding, cur-
rently experiencing menopause or post menopause.38 Women
who did not meet any of these specific life stages were coded as
‘none apply’.38 Information on pregnancy trimester or gestation
was not reported.
Pain severity was assessed by self-report over a duration of four
weeks prior to the survey and classified into four groups for the
purposes of this study; no pain, very mild to mild pain, moderate to
very severe pain and not applicable or unknown.
Participants of the Australian NHS were asked for the name of
all medications they had taken in the last two weeks. It was
requested that participants provide the packages of all recently
taken medications to the interviewer to verify medication name.
Medications within the NHS were classified using the World
Health Organisation’s (WHO) Anatomical Therapeutic Chemical
(ATC) system. The ATC classification system categorises drugs into
different groups by either the organ or system on which they act, as
well as their associated pharmacologic and therapeutic proper-
ties.39 Opioid analgesia use included the use of any type of opioid
analgesia over the previous two-week period. Non-opioid analge-
sia use included the use of any type of pharmaceutical non-opioid
analgesic medications and anti-migraine medications over the
previous two-week period. The survey did not distinguish between
medications that were prescribed or purchased ‘over the counter’.
Data specific to chronic pain was provided directly from the
Australian Bureau of Statistics (ABS) by special request, as this data
was not released as part of the NHS Confidentialised Unit Record
File (CURF). All other data were extracted from the 2011–2012
Australian NHS CURF and ABS Tablebuilder tool.
Cross-tabulations were performed to establish the prevalence
of bodily pain, as well as the prevalence of opioid and other
analgesia use among women of reproductive age in the NHS
sample. STATA v12 was used for analysis. ABS established
weighting was applied to calculate a population estimate and
associated confidence interval for the identified pain and medica-
tion use prevalence rates. The Jackknife delete-1 weighting
method is recommended by the ABS for use with these andeverity and analgesia use in Australian women of reproductive age,
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reduce potential bias.40 All analysis requiring data specific to
chronic pain were performed by the ABS for the purposes of this
study. Differences between pregnant and non-pregnant groups of
women were tested for significance. A p-value of 0.05 was
regarded as statistically significant.
2.1. Ethics
All interview components of the NHS were conducted by the
Australian Bureau of Statistics staff under the Census and Statistics
Act 1905. These data are made available by the ABS in a CURF. Each
CURF contains detailed participant data collected by the ABS
during the Census and other surveys. This data is then made
available at the discretion of the ABS. Analysis of the CURF data
were undertaken by authors who are registered users of the NHS
CURF. As access to chronic pain data was restricted and not
available as part of the CURF, all analyses of chronic pain data
presented were conducted by the ABS for this study.
3. Results
3.1. Demographics of pregnant and non-pregnant women
Population estimates of demographic information for Austra-
lian women are included in Table 1. Of women aged 15–49 years,
the mean age of pregnant women was 30 years and that of non-
pregnant women 32 years. History of comorbidity was similarTable 1
Weighted population estimates of demographic characteristics.
Females aged 15–49 years
Pregnant women (n = 166, N = 192,617) 
Age (years) 30.3 (29.3–31.3) 
15–19 2.3 (1.6–6.2) 
20–24 13.9 (5.8–22.1) 
25–29 30.9 (21.5–40.3) 
30–34 32.3 (23.4–41.2) 
35–39 16.1 (9.7–22.6) 
40–44 3.5 (0.2–6.8) 
45–49 0.9 (0.0–2.8) 
Marital Status
Never married 25.9 (16.6–35.1) 
Widowed 0.0 – 
Divorced 2.9 (0.0–5.8) 
Separated 0.7 (0.0–2.0) 
Married 71.5 (60.5–80.6) 
History of comorbidity
Asthma 16.7 (10.5–22.9) 
Cancer 5.8 (1.0–10.6) 
Cardiovascular 16.1 (9.2–22.9) 
Arthritis 2.2 (0.0–6.1) 
Osteoporosis 1.1 (0.0–3.1) 
Diabetes 10.3 (2.9–17.8) 
Kidney disease 1.0 (0.0–2.6) 
Sight/hearing 55.5 (46.0–65.1) 
Mental wellbeing 7.3 (2.4–12.1) 
Other conditionsa 43.3 (34.0–52.5) 
No conditions 14.6 (7.4–21.7) 
Smoker
Current daily smoker 9.3 (2.4–16.2) 
Past daily smoker, still smoking 0.0 – 
Past daily smoker, ex-smoker 28.9 (21.2–36.5) 
Never smoked daily 3.6 (0.7–6.5) 
Never smoked 58.2 (48.4–68.1) 
Notes: Data is presented as mean (95% confidence interval) for continuous variables and p
at Australian Bureau of Statistics 54.
a Other conditions’ consisted of over 20 other long-term health conditions including
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issues, arthritis, mental health and ‘other’ health issues were
reported by greater percentages of women who were not pregnant
at the time of the survey. Most women from both groups had never
smoked (58.2% for pregnant women and 60.2% for non-pregnant
women).
3.2. Prevalence of pain in women of reproductive age
The percentage of non-pregnant Australian women aged 15–49
years with chronic or reoccurring pain (for at least a six-month
period) was estimated at 9.7%, compared to 5.0% of women who
were identified as pregnant at the time of the survey.
Very mild to mild pain was the most common severity of bodily
pain reported in pregnant (52.4%) and non-pregnant women
(40.1%), which was found to be a statistically significant difference
(p = 0.023) (Fig. 1). Moderate to very severe pain was experienced
by 17.6% of pregnant women and 22.1% of non-pregnant women
(p = 0.296). The percentage of pregnant and non-pregnant women
experiencing no pain during the four weeks prior to the interview
were similar (29.6% and 29.7% respectively; p = 0.990).
3.3. Use of opioid and non-opioid analgesia in women of reproductive
age with pain
Population estimates indicate that 1383 (0.7%) of pregnant
women and 138,962 (2.6%) of non-pregnant women aged 15–49
years had taken opioid analgesia within the two weeks prior to theNon-pregnant women (n = 4710, N = 5,256,154)
32.3 (32.2–32.3)
14.2 (13.0–15.3)
13.5 (12.3–14.6)
14.5 (14.1–14.9)
13.6 (13.3–13.9)
14.4 (14.1–14.6)
15.1 (15.0–15.2)
14.8 (14.6–14.9)
49.0 (47.5–50.5)
0.3 (0.2–0.5)
4.9 (4.2–5.7)
3.2 (2.6–3.8)
42.5 (40.9–44.2)
23.1 (21.4–24.8)
5.2 (4.5–5.9)
23.9 (22.2–25.7)
6.3 (5.6–7.0)
0.8 (0.5–1.1)
7.3 (6.4–8.2)
1.4 (1.0–1.8)
53.0 (51.2–54.9)
17.4 (16.0–18.9)
58.7 (56.7–60.7)
14.0 (12.5–15.4)
15.9 (14.7–17.1)
1.4 (0.8–2.0)
18.5 (17.1–20.0)
4.0 (3.4–4.6)
60.2 (58.5–61.8)
ercent (95% confidence interval) for categorical variables. Further detail is available
; sinusitis, food allergy, drug allergy, anaemia, epilepsy, migraine and psoriasis.
everity and analgesia use in Australian women of reproductive age,
Fig. 1. Pain severity during previous four weeks by pregnancy status in women aged 15–49 years.
Notes: Reported pain severity was tested between pregnant and non-pregnant groups of women. Significance of difference between group proportions represented by P-
values; A < 0.05; B < 0.001. Error bars represent 95% confidence intervals for estimates.
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analgesia (opioid and non-opioid), compared with 27.3% of non-
pregnant women of reproductive age with chronic pain. One
hundred percent of women reporting the use of opioid analgesia
during pregnancy had pain which was described as moderate to
very severe (Fig. 2a). In non-pregnant women, most women who
took opioids reported moderate to very severe pain (66.0%),
followed by very mild to mild pain (25.5%) and then no pain (6.1%).
The pain status of a small proportion of non-pregnant women
using opioid medications was not known.Fig. 2. (a and b) Pain severity over previous four weeks in women taking (A) opioid an
Notes: Reported pain severity was tested between pregnant and non-pregnant groups
proportions represented by P-values; A <0.05; B <0.001; C <0.001. Error bars represent
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moderate to very severe pain when taking opioid analgesia than
non-pregnant women of reproductive age (p < 0.001), whilst non-
pregnant women were significantly more likely to report no pain
(p = 0.005) or very mild to mild pain (p < 0.001) (Fig. 2a). Of all
pregnant women with moderate to very severe pain 4.1% took
opioid analgesia; and of non-pregnant women with moderate to
very severe pain 7.9% took opioid analgesia.
Estimates of non-opioid analgesia use indicate that 10,024
(5.2%) pregnant women and 547,731 (10.4%) non-pregnant womenalgesic medications and (B) non-opioid analgesic medications aged 15–49 years.
 of women using opioid analgesic medications. Significance of difference between
 95% confidence intervals for estimates.
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with and without pain used non-opioid analgesia during the two
weeks prior to the interview, with the majority (50.8%) reporting
no pain over the previous four weeks (Fig. 2b). As seen in this
figure, confidence intervals for pregnancy and non-opioid analge-
sia use were wide.
One quarter (25.8%) of pregnant women using non-opioid
analgesia experienced very mild to mild pain and 23.8% reported
moderate to very severe pain. One in five (20.3%) non-pregnant
women reported using non-opioid analgesia in the previous two
weeks when they had no pain. This proportion increased to 37.6%
for non-pregnant women with very mild to mild pain and 35.9% for
moderate to very severe pain. The pain status of a small proportion
of women aged 15 to 49 years taking non-opioid analgesia was not
known. There were no significant differences in pain severity
between pregnant and non-pregnant women taking non-opioid
analgesia in this study.
4. Discussion
Internationally, the prevalence of chronic pain in pregnant
women has not been widely reported, although it is an issue
gaining more recognition in the literature.4,5,41 Based on the
Australian NHS we estimate that twice as many non-pregnant
women of reproductive age suffer from chronic or reoccurring pain
than women who are pregnant, at 10% and 5% respectively. For
non-pregnant women this is at the lower end of previous
Australian estimates which ranged between 10–17% across this
age-group.2 Some of the difference between groups seen in the
current study may be explained by higher reported prevalence of
specific chronic conditions in non-pregnant women, such as
arthritis.
An estimated 17% of pregnant women and 22% of non-
pregnant women experienced moderate to very severe pain in the
most recent four weeks. There were no pregnant women who
reported experiencing very severe pain. It is possible that any
pregnant woman experiencing such a severe degree of pain would
be hospitalised for further investigation and as a result, would not
have participated in the survey. Absence of pregnant women with
very severe pain in these results may also indicate that women
with pain of such severity may not consider pregnancy due to the
increased physical burden they may face, including their
perceived ability to care for the infant. Indeed, the adverse
effects of severe pain on the quality of life of sufferers are well
acknowledged.42,43 Yet, results of the few studies exploring
attitudes towards pregnancy in women living with chronic,
painful conditions have found that many women do not
necessarily see their condition as an absolute deterrent to
pregnancy.44,45 A further consideration is that perception of pain
severity may differ between pregnant and non-pregnant women.
This issue has not been well researched. It is possible that each of
these factors (and potentially many others) play a role in the
differences observed in this study.
Given constraints on the release of chronic pain data by the ABS
we were unable to determine the exact proportion of pregnant
women with chronic pain who were taking opioid analgesia.
However, we did ascertain that almost 14% of pregnant women and
almost double, 27% of non-pregnant women who experienced
chronic pain had taken some form of analgesic medication (opioid
and/or non-opioid) within the most recent two-week period. In
other Australian research reporting prevalence of analgesia use in
pregnancy, a 2002–05 Western Australian study revealed that 8.3%
of prescriptions dispensed during pregnancy were for analgesic
medications.46 However, as the data related to prescriptions rather
than the population who were pregnant, it is not possible to
directly compare these findings with the current study.Please cite this article in press as: A.M. Miller, et al., Chronic pain, pain s
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for the prescribing of opioid analgesic medications, it was a
reassuring finding that women who reported moderate to very
severe levels of pain were found to have the highest prevalence of
opioid analgesia use. When looking at all pregnant women who
reported pain over the previous four weeks, only four percent of
those who had moderate to very severe pain reported the use of
opioid analgesic medications. In the sample, these women were all
taking codeine combination medications. Codeine is available
alone, or in combination with paracetamol or ibuprofen in
Australia. At the time the data was collected for this study, many
lower dose codeine-combination formulations (i.e. 15 mg co-
deine per tablet) were still available without a prescription.
However, from February 2018, all codeine medications must be
prescribed by a doctor. Risk of infant withdrawal with low dose
codeine medications is still possible with prolonged use in late
pregnancy.47
In non-pregnant women, a quarter of all those with very mild to
mild levels of pain, and 10% of those who reported no pain at all
over the previous four weeks reported recently taking opioid
analgesic medication. These medications included: codeine,
tramadol, oxycodone, buprenorphine and morphine. Interestingly,
the survey did not capture any women of reproductive age who
reported their opioid medication use was for opioid maintenance
therapy to treat substance dependence. As a result, the reasons for
use in women with no or very mild to mild pain is unclear.
However, recall bias and reporting bias may be attributing factors.
Non-opioid analgesics are some of the most commonly used
medications during the pregnancy period.48 Previous Australian
estimates have reported that over half of pregnant women had
taken non-opioid analgesia during at least one trimester of
pregnancy.49 The current study reported a lower overall estimate
at 5% of pregnant women, which may be reflective of both the
duration of reported medication use as well as recall bias.
Examination of pain status alongside non-opioid analgesia use
in the current study provided some divergent results. For
instance, less than a quarter of pregnant women with moderate
to very severe pain reported the use of any non-opioid analgesia
whereas, over half of pregnant women who stated they had taken
non-opioid analgesia over the last two weeks reported no pain. It
could be argued that medications such as paracetamol may have
been utilised for their antipyretic properties. However, it is
unlikely that use in this manner accounts for all women who
reported using non-opioid analgesia whilst pregnant. These
results may suggest that women consider non-opioid medica-
tions as ‘safe’ overall during pregnancy. This is not always the
case. Non-steroidal anti-inflammatory drugs have recently been
identified as a causal factor in increased risk of miscarriage, even
if only taken around the time of conception.50 Paracetamol has
also caused concern, with associations made between use in
pregnancy and subsequent development of asthma51 and
behavioural problems52 in childhood.
The strengths of this study include the use of data collected in a
robust and rigorous manner by trained staff of the Australian
Bureau of Statistics as part of the 2011-12 Australian National
Health Survey. The NHS as part of the Australian Health Survey is
the largest, most extensive health survey ever conducted in
Australia, with a response rate of over 80%. It is the most recent
NHS for which pregnancy status was assessed, as this detail was
not included in the 2014-15 version of the survey.
Regarding study limitations, the Australian NHS survey relies
mainly upon self-reported data. While this may be less of an issue
for variables such as chronic pain or pain severity, where self-
report is considered the gold standard, it could be argued that
self-report of medication use may not be as robust a measure as
methods such as medical record audit or utilising linkedeverity and analgesia use in Australian women of reproductive age,
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women may not disclose or may underreport the use of
substances (both legal and illegal). However, the fact that
participants were asked to provide the interviewer with the
medications they had taken over the previous two weeks lends
strength to the study, improving the quality of the data collected
over self-reported medication use alone. Irrespective, as medica-
tion data were recorded by ATC classification alone, it was not
possible to distinguish between analgesic medications available
over the counter or those which are only available by prescription.
This study also only captured the use of analgesic medications
over a two-week period out of an entire pregnancy, usually
around 40 weeks duration. Therefore, our results will likely
underestimate the true proportion of Australian women of
childbearing age who take opioid or non-opioid analgesia during
their pregnancy.
It is also possible that women who participated in the survey
may have been pregnant but unaware at the time of the survey or
be unwilling to disclose their pregnancy to the interviewer when
asked. It is also important to acknowledge that prevalence of
chronic pain increases with age whilst fecundity decreases. Thus,
the prevalence of chronic pain in this study is likely to be
inherently higher in the non-pregnant group as the group of
pregnant women had proportionally fewer participants aged 40 to
49 years. The option of adjusting for age in the comparison, was not
possible due to the constraints on statistical analysis of the data,
including pre-analysis of the chronic pain data for us by the ABS.
Large relative standard errors for some chronic pain data were due
to the small number of participants and likewise large confidence
intervals in data for pregnant women, suggesting that some
weighted estimates should be used with caution. Some confidence
intervals have been truncated in Table 1 and Fig. 2 where illogical
results were obtained (i.e. greater than 100% or less than 0%). This
circumstance arose as part of the weighting process due to the
small sample size of the pregnant group. We were not able to
distinguish whether the reported severity of bodily pain improved
or changed because of recent analgesia use. Nor were we able to
establish whether the pain which was reported preceded
pregnancy or vice versa.
The results of this study also raise questions about decision
making in relation to pain treatment in pregnant women. Does
perceived pain need to be more severe for pregnant women to
consider taking strong analgesic medications during pregnancy?
Are pregnant women more likely to remain untreated, even for
pain which is moderate to very severe? If so, do we need to increase
access to information and education on safety of pain relief during
pregnancy?
5. Conclusion
Approximately 1 in 20 women have chronic pain during
pregnancy in Australia. Opioid analgesia use was reported by
around 1% of pregnant Australian women and non-opioid analgesia
by 5% over a two-week duration. Use of opioids in Australian
pregnant women is associated with moderate to very severe pain,
whilst use of non-opioid analgesia is not always used in association
with pain. However, the true number of women of reproductive
age who are taking opioid analgesia may be much higher than the
results of this study suggest. Irrespective of prevalence, all women
taking medication during pregnancy require, at the very minimum,
accurate, up-to-date information on the risks and benefits of their
specific medication. In turn, health professionals need further
evidence on pain and the use of opioid analgesia during pregnancy
and more information on the decision-making processes of
pregnant women experiencing pain to assist them with the care
of their patients.Please cite this article in press as: A.M. Miller, et al., Chronic pain, pain s
Women Birth (2018), https://doi.org/10.1016/j.wombi.2018.06.013Conflicts of interest
Ms Miller, Professor Sanderson and Dr Breslin have no conflicts
of interest to declare. Dr Neil would like to acknowledge that she
lives with a chronic pain condition. Associate Professor Bruno has
been an investigator on untied investigator driven educational
grants from Reckitt Benckiser and has received an untied
educational grant from Mundipharma for post-marketing surveil-
lance studies of Reformulated OxyContin1. These untied grants are
all unrelated to the current study which has been submitted for
consideration to your journal.
Acknowledgements
The authors wish to acknowledge the comments and feedback
provided by Professor Peter Dargaville during preparation of the
manuscript and the grant received by the Local Government
Association of Tasmania which was used to fund the statistical
analysis of chronic pain related data by the Australian Bureau of
Statistics. AM’s work was supported by an Australian Postgraduate
Award Scholarship and a Staples Australia Konica Minolta Elite
Research Scholarship. AN’s work was supported by a Select
Foundation Research Fellowship.
References
1. Meisler J.G.. Chronic pain conditions in women. J Womens Health 1999;8
(3):313–20.
2. Blyth FM, March LM, Brnabic AJ, Jorm LR, Williamson M, Cousins MJ. Chronic
pain in Australia: a prevalence study. PAIN1 2001;89(2–3):127–34.
3. Australian Bureau of Statistics. Characteristics of Bodily Pain in Australia. 2012
http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/4841.0Chapter12011.
[Accessed 24 April 2015].
4. Coluzzi F, Valensise H, Sacco M, Allegri M. Chronic pain management in
pregnancy and lactation. Minerva Anestesiol 2014;80(2):211–24.
5. Pritham UA, McKay L. Safe management of chronic pain in pregnancy in an era
of opioid misuse and abuse. J Obstet Gynecol Neonatal Nurs 2014;43(5):554–67.
6. Brennan MC, Rayburn WF. Counseling about risks of congenital anomalies from
prescription opioids. Birth Defects Res A Clin Mol Teratol 2012;94(8):620–5.
7. Kellogg A, Rose CH, Harms RH, Watson WJ. Current trends in narcotic use in
pregnancy and neonatal outcomes. Am J Obstet Gynecol 2011;204(3) 259.e1-4.
8. Broussard CS, Rasmussen SA, Reefhuis J, et al. Maternal treatment with opioid
analgesics and risk for birth defects. Am J Obstet Gynecol 2011;204(4) 314.e1-.
e11.
9. Sharpe C, Kuschel C. Outcomes of infants born to mothers receiving
methadone for pain management in pregnancy. Arch Dis Child Fetal Neonatal
Ed 2004;89(1):F33–6.
10. Wunsch MJ, Stanard V, Schnoll SH. Treatment of pain in pregnancy. Clin J Pain
2003;19(3):148–55.
11. van Vollenhoven RF. Sex differences in rheumatoid arthritis: more than meets
the eye. BMC Med 2009;7(1):12.
12. Castori M, Dordoni C, Valiante M, et al. Nosology and inheritance pattern(s) of
joint hypermobility syndrome and Ehlers–Danlos syndrome, hypermobility
type: a study of intrafamilial and interfamilial variability in 23 Italian
pedigrees. Am J Med Genet A 2014;164(12):3010–20.
13. LeResche L. Epidemiology of temporomandibular disorders: implications for
the investigation of etiologic factors. Crit Rev Oral Biol Med 1997;8(3):291–305.
14. Frederick IO, Qiu C-f, Enquobahrie DA, et al. Lifetime Prevalence and Correlates
of Migraine among Women in a Pacific Northwest Pregnancy Cohort Study.
Headache 2014;54(4):675–85.
15. Sabino J, Grauer JN. Pregnancy and low back pain. Curr Rev Musculoskelet Med
2008;1(2):137–41.
16. Mogren IM, Pohjanen AI. Low back pain and pelvic pain during pregnancy:
prevalence and risk factors. Spine (Phila Pa 1976) 2005;30(8):983–91.
17. Weir PT, Harlan GA, Nkoy FL, et al. The incidence of fibromyalgia and its
associated comorbidities: a population-based retrospective cohort study
based on International Classification of Diseases, 9th Revision codes. J Clin
Rheumatol 2006;12(3):124–8.
18. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and
characteristics of fibromyalgia in the general population. Arthritis Rheum
1995;38(1):19–28.
19. Beaulieu DB, Kane S. Inflammatory bowel disease in pregnancy. World J
Gastroenterol 2011;17(22):2696–701.
20. Eskenazi B, Warner ML. Epidemiology of endometriosis. Obstet Gynecol Clin
North Am 1997;24(2):235–58.
21. Ayorinde AA, Bhattacharya S, Druce KL, Jones GT, Macfarlane GJ. Chronic pelvic
pain in women of reproductive and post-reproductive age: a population-based
study. Eur J Pain 2017;21(3):445–55.everity and analgesia use in Australian women of reproductive age,
A.M. Miller et al. / Women and Birth xxx (2018) xxx–xxx 7
G Model
WOMBI 822 No. of Pages 722. Albert H, Godskesen M, Westergaard J. Prognosis in four syndromes of
pregnancy-related pelvic pain. Acta Obstet Gynecol Scand 2001;80(6):505–10.
23. Gutke A, Östgaard HC, Öberg B. Predicting persistent pregnancy-related low
back pain. Spine (Phila Pa 1976) 2008;33(12):E386–93.
24. Stapleton DB, MacLennan AH, Kristiansson P. The prevalence of recalled low
back pain during and after pregnancy: a South Australian population survey.
Aust N Z J Obstet Gynaecol 2002;42(5):482–5.
25. Jain S, Eedarapalli P, Jamjute P, Sawdy R. Symphysis pubis dysfunction: a
practical approach to management. Obstet Gynaecol 2006;8(3):153–8.
26. Mogil JS. Pain genetics: past, present and future. Trends Genet 2012;28(6):258–
66.
27. Freynhagen R, Geisslinger G, Schug SA. Opioids for chronic non-cancer pain.
BMJ 2013;346:f2937.
28. Tolia VN, Patrick SW, Bennett MM, et al. Increasing incidence of the neonatal
abstinence syndrome in U.S. neonatal ICUs. New Engl J Med 2015;372
(22):2118–26.
29. Patrick SW, Dudley J, Martin PR, et al. Prescription opioid epidemic and infant
outcomes. Pediatrics 2015;135(5):842–50.
30. Turner SD, Gomes T, Camacho X, et al. Neonatal opioid withdrawal and
antenatal opioid prescribing. CMAJ Open 2015;3(1):E55–61.
31. Engeland A, Bramness JG, Daltveit AK, Rønning M, Skurtveit S, Furu K.
Prescription drug use among fathers and mothers before and during
pregnancy: a population-based cohort study of 106 000 pregnancies in
Norway 2004–2006. Br J Clin Pharmacol 2008;65(5):653–60.
32. Bateman BT, Hernandez-Diaz S, Rathmell JP, et al. Patterns of opioid utilization
in pregnancy in a large cohort of commercial insurance beneficiaries in the
United States. Anesthesiology 2014;120(5):1216–24.
33. Buhimschi CS, Weiner CP. Medications in pregnancy and lactation: part 1.
Teratology. Obstet Gynecol 2009;113(1):166–88.
34. Rayburn WF, Brennan MC. Periconception warnings about prescribing opioids.
Am J Obstet Gynecol 2011;204(4)281–2 2p.
35. Yazdy MM, Mitchell AA, Tinker SC, Parker SE, Werler MM. Periconceptional use
of opioids and the risk of neural tube defects. Obstet Gynecol 2013;122(4):838–
44.
36. Australian Bureau of Statistics. Australian Health Survey: Users’ Guide, 2011–13
Survey Design and Operation. 2013 http://www.abs.gov.au/ausstats/abs@.nsf/
Latestproducts/D9707300945AE90FCA257B8D00229E78?opendocument.
[Accessed 30 July 2015].
37. Australian Bureau of Statistics. Australian Health Survey: Users’ Guide, 2011-13
Structure of the Australian Health Survey. 2013 http://www.abs.gov.au/ausstats/
abs@.nsf/Latestproducts/74D87E30B3539C53CA257BBB0014BB36?opendo-
cument. [Accessed 10 October 2015].
38. Australian Bureau of Statistics. Australian Health Survey: Users’ Guide, 2011-13
Female life stages. 2013 http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/Please cite this article in press as: A.M. Miller, et al., Chronic pain, pain s
Women Birth (2018), https://doi.org/10.1016/j.wombi.2018.06.0130054B41EE12562AACA257B8D00229E95?opendocument. [Accessed 1 Sep-
tember 2016].
39. World Health Organisation. The Anatomical Therapeutic Chemical Classification
System with Defined Daily Doses (ATC/DDD). 2003 http://www.who.int/
classifications/atcddd/en/. [Accessed 15 July 2016].
40. Bell P. Weighting and Standard Error Estimation for ABS Household Surveys. ABS
Methodology Advisory Committee: Australian Bureau of Statistics; 2000.
41. Meyer M. The perils of opioid prescribing during pregnancy. Obstet Gynecol Clin
North Am 2014;41(2):297–306.
42. Turk DC, Wilson HD, Cahana A. Treatment of chronic non-cancer pain. Lancet
2011;377(9784):2226–35.
43. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic
opioid therapy in chronic noncancer pain. J Pain 2009;10(2):113–30.
44. Johnson NS, Harwood EM, Nguyen RHN. You have to go through it and have
your children: reproductive experiences among women with vulvodynia. BMC
Pregnancy Childbirth 2015;15:114.
45. Meade T, Sharpe L, Hallab L, Aspanell D, Manolios N. Navigating motherhood
choices in the context of rheumatoid arthritis: women's stories. Musculoskelet
Care 2013;11(2):73–82.
46. Colvin L, Slack-Smith L, Stanley FJ, Bower C. Pharmacovigilance in pregnancy
using population-based linked datasets. Pharmacoepidemiol Drug Saf 2009;18
(3):211–25.
47. Therapeutic Goods Administraion. Prescribing Medicines in Pregnancy Database.
2016 https://www.tga.gov.au/prescribing-medicines-pregnancy-database.
[Accessed 20 May 2017].
48. Kennedy D. Analgesics and pain relief in pregnancy and breastfeeding. Aust
Prescr 2011;34(1):8–10.
49. Henry A, Crowther C. Patterns of medication use during and prior to
pregnancy: the MAP study. Aust N Z J Obstet Gynaecol 2000;40(2):165–72.
50. Therapeutic Goods Administration. Nonsteroidal Anti-Inflammatory Drugs
(NSAIDs) and Spontaneous Abortion. Canberra: Australian Government
Department of Health; 2016.
51. Shaheen SO, Newson RB, Smith GD, Henderson AJ. Prenatal paracetamol
exposure and asthma: further evidence against confounding. Int J. Epidemiol
2010;39(3):790–4.
52. Stergiakouli E, Thapar A, Davey Smith G. Association of acetaminophen use
during pregnancy with behavioral problems in childhood: evidence against
confounding. JAMA Pediatr 2016;170(10):964–70. doi:http://dx.doi.org/
10.1001/jamapediatrics.2016.1775.
53. Nahin RL. Estimates of pain prevalence and severity in adults: United States,
2012. J Pain 2015;16(8):769–80.
54. Australian Bureau of Statistics. Australian Health Survey: Users’ Guide, 2011–13
Long Term Conditions: Other. 2013 http://www.abs.gov.au/ausstats/abs@.nsf/
Latestproducts/E961C216AABF42E0CA257B8E0016EA5F?opendocument.
[Accessed 10 August 2016].everity and analgesia use in Australian women of reproductive age,
